Asserter profile

NUGEN TECHNOLOGIES, INC.

operating company0 patents now3 ever0 cases filed during tenure4 connections

PTAB exposure

3of this entity’s patents have been challenged at PTAB (6 total proceedings). 3 had claims invalidated.

Final written decisions are public record. The invalidation grounds usually carry over as § 102 / § 103 ammunition in district court — see IPR estoppel.

Two-hop network

Edges marked ⚖️ overlap with at least one infringement suit filed during the receiving entity’s tenure with the patent. Bold-bordered = this entity. Red = NPE; orange = shell LLC; green = defensive aggregator; blue = operating company.

flowchart LR
    Nnugen["NUGEN TECHNOLOGIES, INC."]
    Narmour_chris_amorese_doug_kurn_nurith["ARMOUR, Chris, AMORESE, Doug, KURN, NUR…"]
    Ntecan_genomics["TECAN GENOMICS, INC."]
    Namorese_douglas_schroeder_ben_scolnick_jonathan["AMORESE, DOUGLAS; SCHROEDER, BEN; SCOLN…"]
    Namorese_douglas_schroeder_ben_skolnick_jonathan["AMORESE, DOUGLAS; SCHROEDER, BEN; SKOLN…"]
    Narmour_chris_amorese_doug_kurn_nurith -->|"2018 · Assignment of Assignors Interest · 10876108"| Nnugen
    Nnugen ==>|"⚖️ 2023 · Change of Name · 10876108"| Ntecan_genomics
    Narmour_chris_amorese_doug_kurn_nurith -->|"2017 · Assignment · 10036012"| Nnugen
    Nnugen -->|"2023 · Change of Name · 10036012"| Ntecan_genomics
    Namorese_douglas_schroeder_ben_scolnick_jonathan -->|"2020 · Assignment · 11098357"| Nnugen
    Namorese_douglas_schroeder_ben_skolnick_jonathan -->|"2020 · Assignment · 11098357"| Nnugen
    Nnugen -->|"2021 · Merger · 11098357"| Ntecan_genomics
    classDef focal fill:#fef3c7,stroke:#92400e,stroke-width:3px,color:#1c1917
    classDef npe fill:#fee2e2,stroke:#be123c,stroke-width:2px,color:#1c1917
    classDef shell fill:#fed7aa,stroke:#9a3412,stroke-width:2px,color:#1c1917
    classDef defensive fill:#dcfce7,stroke:#15803d,stroke-width:2px,color:#1c1917
    classDef operating fill:#e0f2fe,stroke:#075985,stroke-width:1px,color:#1c1917
    class Nnugen focal
    class Ntecan_genomics operating

Patents previously held (3)

Connected entities (4)

Correspondent attorneys (2)

Attorneys / firms recorded with USPTO when this entity received a patent. Recurrence is the signal — many firms do both NPE and operating-company patent work, so a single appearance doesn’t mean much.